List view / Grid view
An investment of $50 million by Astellas Pharma in Poseida…
An investment of $50 million by Astellas Pharma in Poseida Therapeutics’ Phase I allogeneic CAR-T product candidate for solid tumour indications is set to advance the cancer immunotherapy field.
Two Big Pharma companies have announced management changes in 2023:…
Two Big Pharma companies have announced management changes in 2023: Astellas will have a new President and CEO and Bayer AG will be led by a new CEO.
Adam Pearson, Senior Oncology Analyst at GlobalData, comments on the…
Adam Pearson, Senior Oncology Analyst at GlobalData, comments on the development of CRISPR-based therapies and outlines potential opportunities and challenges in the space.
